TY - JOUR
T1 - Etoposide-induced hepatic injury
T2 - A potential complication of high-dose therapy
AU - Johnson, D. H.
AU - Greco, F. A.
AU - Wolff, S. N.
PY - 1983/12/1
Y1 - 1983/12/1
N2 - Two cases of toxic hepatitis developing in patients receiving high-dose etoposide (VP-16-213) for refractory germinal neoplasms are described. Each patient received a total cumulative dose of at least 6,800 mg/m2. Liver function abnormalities, including hyperbilirubinemia, elevated transminases, and elevated alkaline phosphatase, became clinically apparent approximately 3 weeks following the last dose of VP-16-213. These abnormalities resolved spontaneously without sequelae over 12 weeks. High-dose VP-16-213 may be associated with hepatic injury.
AB - Two cases of toxic hepatitis developing in patients receiving high-dose etoposide (VP-16-213) for refractory germinal neoplasms are described. Each patient received a total cumulative dose of at least 6,800 mg/m2. Liver function abnormalities, including hyperbilirubinemia, elevated transminases, and elevated alkaline phosphatase, became clinically apparent approximately 3 weeks following the last dose of VP-16-213. These abnormalities resolved spontaneously without sequelae over 12 weeks. High-dose VP-16-213 may be associated with hepatic injury.
UR - http://www.scopus.com/inward/record.url?scp=0021073168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021073168&partnerID=8YFLogxK
M3 - Article
C2 - 6315228
AN - SCOPUS:0021073168
SN - 0361-5960
VL - 67
SP - 1023
EP - 1024
JO - Cancer Treatment Reports
JF - Cancer Treatment Reports
IS - 11
ER -